This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Emergent BioSolutions Management Presents At JPMorgan SMid Cap Conference (Transcript)

Stocks in this article: EBS

To give everybody and I see some familiar faces here, so I apologize if I go over old news but for those of you who don't know Emergent, we have the only FDA licensed anthrax vaccine, which is BioThrax. We're organized into two divisions, BioDefense, which primarily is focused on the anthrax infectious disease. As well as BioSciences, and that's oncology and autoimmune. And you see those are the three disease areas that we're focused on.

We have eight clinical-stage candidates at this point in time. And we've had nine years of profitability and look forward to completing this year as a profitable biotech as well.

This gives you a very quick overview of the clinical candidates that we have today and it's a mixture of BioD and BioDefense. I'm not going to go through each and every one. That could take up to 20 minutes by itself. I will highlight a couple of them a little bit further into the presentation. You can see we've got a couple in Phase 3, couple in Phase 2, couple in Phase 1. We've also got a number of pre-clinical candidates, which we will not be talking about.

So, to get into the BioDefense division and give you a little bit of background on BioThrax. As I said, it's the only FDA-licensed anthrax vaccine. It's been in over 2.5 million individuals to date. It's got a safety profile, which is well established and quite enviable in the vaccine field. We now have four-year dating on this product and one might say, why is that so special.

Number one, BioThrax is primarily purchased by the government today for stockpiling purposes. So the longer the shelf life, the better. And at four-year dating, we have the longest shelf life of any vaccine that's licensed today.

Today's regimen is five doses over 18 months with an annual boost. We're working on improving that and I'll talk to that in just a moment. We manufacture this at a single manufacturing location. Our current capacity is about 7 million to 9 million doses per year. We're increasing that manufacturing capacity. We've got a new building and I'll take you through some of the details of that in just a moment.

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs